Department of Internal Medicine, Dokuz Eylul University, Faculty of Medicine, Izmir, Turkey.
Department of Geriatric Medicine, Dokuz Eylul University, Faculty of Medicine, Izmir, Turkey; Geriatric Sciences Association, Izmir, Turkey.
Exp Gerontol. 2022 Jul;164:111832. doi: 10.1016/j.exger.2022.111832. Epub 2022 May 6.
Sarcopenia is associated with increased morbidity and mortality in older adults with type 2 diabetes mellitus (T2DM). This study investigates the effects of dipeptidyl peptidase-4 inhibitors (DPP4i) as an add-on therapy for sarcopenia in older adults with T2DM over a six-month follow-up period.
This is a retrospective and six-month follow-up study. The study was performed on 90 participants who are followed in a geriatric clinic hospital. Sarcopenia was diagnosed as per the EGWSOP-2 criteria. The patients were divided into two groups regarding DPP4i use. Each patient was evaluated for sarcopenia and sarcopenia-related parameters at baseline and at the end of 6 months.
The mean age of the patients was 72.57 ± 7.089, and 60% of them were female. DPP4i users had worse glycemic control and decreased rate of low muscle strength at the end of 6 months (39.6% vs. 25.0%, P = .039). Forty-two patients without DPP4i therapy had reduced muscle strength (22.71 ± 6.95 kg vs. 20.88 ± 6.32 kg, P = .046) and stable Hba1c levels (6.45 ± 0.56% vs. 6.40 ± 0.52, P = .380) at their six-month follow-up control.
Adding DPP4i to treatment for T2DM yields a positive effect on muscle strength and glycemic control. These agents may offer higher prospects in managing T2DM while counteracting sarcopenia.
T2DM and Sarcopenia are common in older adults. Considering the increased prevalence of T2DM and the risk of coexistent sarcopenia in older adults, the additional positive effects of DPP4i may be crucial in the choice of treatment for these patients.
肌少症与 2 型糖尿病（T2DM）老年患者的发病率和死亡率增加有关。本研究旨在探讨在 6 个月的随访期间，二肽基肽酶-4 抑制剂（DPP4i）作为 T2DM 老年患者肌少症的附加治疗的效果。
这是一项回顾性和 6 个月随访研究。研究对象为在老年科医院随访的 90 名患者。根据 EGWSOP-2 标准诊断肌少症。根据是否使用 DPP4i 将患者分为两组。每位患者在基线和 6 个月时均进行肌少症和肌少症相关参数评估。
患者的平均年龄为 72.57 ± 7.089 岁，其中 60%为女性。在 6 个月时，DPP4i 使用者的血糖控制更差，肌肉力量下降的比例更低（39.6% vs. 25.0%，P = 0.039）。未接受 DPP4i 治疗的 42 名患者肌肉力量减弱（22.71 ± 6.95 kg vs. 20.88 ± 6.32 kg，P = 0.046），HbA1c 水平稳定（6.45 ± 0.56% vs. 6.40 ± 0.52%，P = 0.380）。
在 T2DM 治疗中添加 DPP4i 对肌肉力量和血糖控制有积极影响。这些药物在治疗 T2DM 的同时可能对抗肌少症方面提供更高的前景。
T2DM 和肌少症在老年人中很常见。考虑到 T2DM 的患病率增加以及老年人同时存在肌少症的风险，DPP4i 的额外积极作用对于这些患者的治疗选择可能至关重要。
